Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Donor Lymphocyte Infusion

Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome

Bone Marrow Transplantation volume 33, pages 531–534 (2004)Cite this article

Summary:

Donor lymphocyte infusion has become established as a salvage therapy for patients with hematological disorders relapsing after allogeneic bone marrow transplantation (BMT). The role of donor lymphocyte infusion for patients with myelodysplastic syndrome (MDS) remains to be established. Between July 1993 and October 2001, 14 patients with MDS relapsing after allogeneic BMT received DLI as salvage therapy. At the time of BMT, one patient had RA, nine had RAEB, of whom three were in CR after induction-type chemotherapy, two had RAEB-T, one had CMML and one had AML. Donors were HLA-matched siblings (n=12), HLA-matched other relative (n=1) and unrelated (n=1). At the time of relapse, the median marrow blast count was 9%. The median CD3+ cell dose administered was 6.3 × 107/kg. With a median follow-up of 49 months, six patients were alive, of whom two were in CR after DLI alone and remained disease-free, two were in CR after a second BMT and two had active disease. Eight patients died of disease progression. Although DLI alone seems to be effective in a small number of patients with MDS, other treatment strategies, including prior debulking chemotherapy, deserve investigation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Picozzi Jr VJ, Swanson GF, Morgan R et al. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 1986; 4: 589–595.

    Article  PubMed  Google Scholar 

  2. Koeffler HP, Hirji K, Itri L . 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69: 1399–1407.

    CAS  PubMed  Google Scholar 

  3. Elias L, Hoffman R, Boswell S et al. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia 1987; 1: 105–110.

    CAS  PubMed  Google Scholar 

  4. Gradishar WJ, Le Beau MM, O'Laughlin R et al. Clinical and cytogenetic responses to granulocyte–macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood 1992; 80: 2463–2470.

    CAS  PubMed  Google Scholar 

  5. Anderson JE, Appelbaum FR, Fisher LD et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681.

    CAS  PubMed  Google Scholar 

  6. Sutton L, Chastang C, Ribaud P et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Societe Francaise de Greffe de Moelle. Blood 1996; 88: 358–365.

    CAS  PubMed  Google Scholar 

  7. Arnold R, de Witte T, van Biezen A et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998; 21: 1213–1216.

    Article  CAS  PubMed  Google Scholar 

  8. Yakoub-Agha I, de La Salmoniere P, Ribaud P et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients – report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963–971.

    Article  CAS  PubMed  Google Scholar 

  9. Cullis JO, Schwarer AP, Hughes TP et al. Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning. Br J Haematol 1992; 80: 33–39.

    Article  CAS  PubMed  Google Scholar 

  10. Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39–42.

    CAS  PubMed  Google Scholar 

  11. Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461–466.

    Article  CAS  PubMed  Google Scholar 

  12. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

    CAS  PubMed  Google Scholar 

  13. Drobyski WR, Hessner MJ, Klein JP et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999; 94: 434–441.

    CAS  PubMed  Google Scholar 

  14. Porter DL, Collins Jr RH, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214–1221.

    CAS  PubMed  Google Scholar 

  15. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  PubMed  Google Scholar 

  16. Collins Jr RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  17. Porter DL, Roth MS, Lee SJ . Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 975–980.

    CAS  PubMed  Google Scholar 

  18. Helg C, Starobinski M, Jeannet M, Chapuis B . Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998; 29: 301–313.

    Article  CAS  PubMed  Google Scholar 

  19. Shiobara S, Nakao S, Ueda M et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769–774.

    Article  CAS  PubMed  Google Scholar 

  20. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  PubMed  Google Scholar 

  21. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  22. Novitzky N, Rubinstein R, Hallett JM et al. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. Transplantation 2000; 69: 1358–1363.

    Article  CAS  PubMed  Google Scholar 

  23. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  24. Sierra J, Perez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997–2004.

    CAS  PubMed  Google Scholar 

  25. Guardiola P, Runde V, Bacigalupo A et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370–4378.

    Article  CAS  PubMed  Google Scholar 

  26. Kroger N, Schetelig J, Zabelina T et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001; 28: 643–647.

    Article  CAS  PubMed  Google Scholar 

  27. Parker JE, Shafi T, Pagliuca A et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144–154.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service des Maladies du Sang, CHRU de Lille, France

    S Depil, E Deconinck, N Milpied, L Sutton, F Witz, J P Jouet, G Damaj & I Yakoub-Agha

Authors
  1. S Depil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Deconinck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Witz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J P Jouet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Damaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Société Française de Greffe de Moelle et Thérapie cellulaire (SFGM-TC)

Corresponding author

Correspondence to I Yakoub-Agha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Depil, S., Deconinck, E., Milpied, N. et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33, 531–534 (2004). https://doi.org/10.1038/sj.bmt.1704381

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704381

Keywords

This article is cited by

Search

Advanced search

Quick links